Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer

Autor:	Edward Wang, Breelyn A. Wilky, Jennifer Buell, E. Dow, David Savitsky, Hagop Youssoufian, Ana M. Martín González, Olga Shebanova, W. Ortuzar, R.B. Stein, Christopher D. Dupont, S. Coulter, J. Wang, Joyce F. Liu, Kathleen N. Moore, C. Drescher, David M. O'Malley, Vivek Subbiah, G. Yuan
Rok vydání:	2018
Předmět:	Oncology Cervical cancer medicine.medical_specialty business.industry medicine.drug_class Cancer Hematology Monoclonal antibody medicine.disease Advanced cancer Internal medicine Relapsed refractory Dose escalation Medicine Open label Anti-PD-1 Monoclonal Antibody business
Zdroj:	Annals of Oncology. 29:viii412-viii413
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::21d5c341f89b47f3579b5c1785c608f6 https://doi.org/10.1093/annonc/mdy288.031 Zobrazit plný text záznamu